Vishal Bhardwaj, popularly known as the ‘Ankle Assassin’ and ‘Ankle Breaker’ for his devastating ankle holds, has been a household name in Pro Kabaddi League (PKL). As the PKL 2024 kicked ...

Karuna Pandey, star of "Pushpa Impossible," embraces the challenge of playing both Pushpa and her lookalike, Basanti. From enduring an on-set toe injury to mastering rural skills like lighting a ...

Former AAP councillor Ram Narayan Bhardwaj on Monday joined the BJP at the party's Delhi unit office in yet another setback for the ruling party ahead of the Delhi Assembly elections.

This project has been a long-desired ambition. Initially, Bhardwaj envisioned a biopic on Sapna Didi, with the late Irrfan Khan portraying Ustara alongside Deepika Padukone. Although that project ...

After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 million in series B funds to support the journey to key clinical ...

The 'Dune' universe expands with 'Dune: Prophecy', a series set 10,000 years before the films. It focuses on the rise of the Bene Gesserit post-Butlerian Jihad. Starring Emily Watson and Olivia ...

Chef Akshay Bhardwaj leads the kitchen at Junoon, one of New York City's best-known Indian restaurants, but when it comes to comfort meals, he often reaches for a bowl of butter chicken.

In 'Pushpa Impossible', Karuna Pandey’s character Pushpa faces new drama as her lookalike, Basanti, arrives with a mysterious agenda. Basanti, tougher and more blunt than Pushpa, disrupts the ...

Actor Shahid Kapoor, who collaborated with ace filmmaker Vishal Bhardwaj for movies like 'Haider', 'Kaminey' and 'Rangoon', is set to begin filming his yet-untitled action thriller with Triptii ...

Indian wheat prices have jumped to a record high due to strong demand, limited supplies, and a delay in the government releasing stocks from its warehouses to augment supplies, industry officials ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.